Let's Talk About It
The Time is Now
Mitapivat is a potential new therapy for the pain crises and anemia of sickle cell disease. There have already been smaller studies for mitapivat. Now it's time to move into a larger clinical trial — RISE UP, a phase 2/3 study.
How Rise Up Works
Warriors who enroll will take either mitapivat or placebo twice a day, every day, for 3 months (phase 2) or for 1 year (phase 3). After that, participants can choose to continue taking mitapivat, or switch from placebo to mitapivat, for up to approximately 4 years (216 weeks) as part of the open-label extension period of the study.
How Mitapivat May Work
Learn about the potential benefits and risks of mitapivat and the goal of the RISE UP clinical trial.